FDA Approves Sanofi's Diabetes Drug for Pediatric Patients Amid Controversy
The FDA has granted approval for a Sanofi diabetes treatment aimed at young patients, following a contentious internal dispute within the agency.
On June 13, 2026, the FDA announced its approval of a new diabetes treatment developed by Sanofi for young patients diagnosed with stage 3 diabetes.
This approval comes after a notable disagreement between career staff at the FDA and the politically appointed head of the Center for Drug Evaluation and Research (CDER).
The decision reflects ongoing debates within the agency regarding the approval processes for new medications, particularly those aimed at vulnerable populations such as children.
Updates
Update at 13:22 UTC on 2026-06-13
STAT reported The FDA has approved a drug that was previously caught in a dispute between career staff and the political appointee head of the CDER.
Sources: STAT